Kempbio provides bioservices to the biotechnology and biopharmaceutical industry. Polyplus-transfection said that by signing this license, Kempbio becomes one of its sub-licensees for the use of PEI technology for the expression of proteins on milligram and gram scales using the human cell line HEK-293 and other mammalian host cells.
The production of recombinant proteins in human cell lines results in authentic human post-translational processing providing advantages for the stability and biological activity of proteins useful in the development of human therapeutics and diagnostic reagents.
Mark Bloomfield, CEO of Polyplus-transfection, said: “We are truly delighted to sign this license agreement with Kempbio. PEI is clearly the reagent of choice for research into large-scale mammalian transient transfection, and this agreement allows Kempbio to use PEI for its transfection services offering.
“Our business relationship with Kembio also demonstrates the significant value of our intellectual property rights in the field of PEI-mediated nucleic acid delivery.”